Tango Therapeutics Inc (TNGX)
6.91
-0.18
(-2.54%)
USD |
NASDAQ |
May 24, 16:00
6.90
-0.01
(-0.14%)
After-Hours: 20:00
Tango Therapeutics SG&A Expense (Quarterly): 10.66M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 10.66M |
| December 31, 2023 | 9.105M |
| September 30, 2023 | 9.209M |
| June 30, 2023 | 9.174M |
| March 31, 2023 | 8.013M |
| December 31, 2022 | 7.887M |
| September 30, 2022 | 8.099M |
| June 30, 2022 | 7.232M |
| Date | Value |
|---|---|
| March 31, 2022 | 6.807M |
| December 31, 2021 | 6.066M |
| September 30, 2021 | 4.433M |
| June 30, 2021 | 3.63M |
| March 31, 2021 | 3.467M |
| December 31, 2020 | 3.016M |
| September 30, 2020 | 2.518M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.518M
Minimum
Sep 2020
10.66M
Maximum
Mar 2024
6.621M
Average
7.232M
Median
Jun 2022
SG&A Expense (Quarterly) Benchmarks
| Cytokinetics Inc | 45.50M |
| Aquestive Therapeutics Inc | 10.69M |
| 2seventy bio Inc | 12.66M |
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |